Royalty Pharma (RPRX) Dividends Paid - Common Growth (3y) (2022 - 2026)
Royalty Pharma (RPRX) Dividends Paid - Common Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Paid (Common) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | - |
| 10 | Royalty Pharma | 25.74 Bn | 25.13 Bn | - | 6.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.10% |
| Dec 31, 2025 | 7.13% |
| Sep 30, 2025 | -3.90% |
| Jun 30, 2025 | 0.68% |
| Mar 31, 2025 | 15.97% |
| Dec 31, 2024 | 28.80% |
| Sep 30, 2024 | -37.23% |
| Jun 30, 2024 | -35.15% |
| Mar 31, 2024 | -36.62% |
| Dec 31, 2023 | 27.76% |
| Sep 30, 2023 | -35.57% |
| Jun 30, 2023 | -37.18% |
| Mar 31, 2023 | -40.85% |
| Dec 31, 2022 | -3.62% |
| Sep 30, 2022 | -0.49% |